Soft bash commentary wrangling on some already well-explained yet understandably not perfect issues. Considering the high stake of DCVax platform when approved on his "enterprise" Stupp protocol and TT Fields (Tumor Treating Fields), yes he intended to ignore/downplay the pristine safety profile and the efficacy evidence resulted from unprecedented efficacy on rGBM patients. I bought 30k shares more today after a while of hesitation after reading his commentary.
BTW, below is my email to him sent this morning:
On your commentary titled "2022 Top Story in Oncology: DCVax in Patients With Newly Diagnosed and Recurrent Glioblastoma"
Yahoo/Sent
Xxx xxx@yahoo.com>
To:roger.stupp@northwestern.edu
Thu, Dec 8 at 1:22 p.m.
Dear Dr. Stupp,
Well first thank you very much for your significant, unmatched contribution to GBM treatment and management over the past decades. Do you think what is important and significant in terms of DCVax-L treatment for GBM patients, besides what you having reasoned and questioned, is its benign safety profile, the strong support of its efficacy from the trial results obtained for rGBM patients? Your suggestion for its full potential with other approved agents in combination is duly appreciated.
Looking forward to your reply,
Sincerely,
xxx, PhD
Market Data 
Markets 
